Key result
Atorvastatin daily improved brachial artery flow-mediated vasodilation in postmenopausal hypercholesterolemic women compared to diet.
Why the study?
Does atorvastatin 10 mg daily improve endothelial function in postmenopausal hypercholesterolemic women?
Does atorvastatin 10 mg daily improve endothelial function in postmenopausal hypercholesterolemic women?
Atorvastatin 10 mg daily significantly improves endothelial reactivity in postmenopausal hypercholesterolemic women as early as 2 weeks into therapy.
Answers are grounded in this paper and cite their sources.
May support early endothelial benefits of low-dose atorvastatin; hypothesis-generating and requires randomized confirmation.
Endothelial dysfunction represents the earliest stage of atherosclerosis and is usually present in hypercholesterolemia. Treatment with statins has been shown to normalize endothelial function in middle-aged men with hypercholesterolemia. We evaluated the effect over time of atorvastatin on the endothelial reactivity in postmenopausal hypercholesterolemic women (mean age, 58 +/- 6 years), receiving atorvastatin, 10 mg daily (n = 20) or American Heart Association step 1 diet (n = 10) for 8 weeks. Lipid profile and brachial artery flow-mediated vasodilation (FMV) were determined at baseline and after 1, 2, 4, and 8 weeks. FMV increased progressively in subjects treated with atorvastatin, and the difference was significant (p < 0.05 vs. baseline) after the second week (baseline 3.8 +/- 3%; first week, 4.8 +/- 3%; second week, 9.2 +/- 3%; fourth week, 11.0 +/- 3%; eighth week, 11.7 +/- 3%). No significant changes were observed in subjects receiving diet (baseline, 3.1 +/- 4%; first week, 2.4 +/- 2%; second week, 2.9 +/- 2%; fourth week, 3.1 +/- 2%; eighth week, 3.3 +/- 2%; p = NS). In the atorvastatin group, low-density lipoprotein (LDL) cholesterol showed a significant decrease since the first week (baseline, 228 +/- 37 mg/dl; first week, 171 +/- 32; second week, 147 +/- 27; fourth week, 139 +/- 29; eighth week, 135 +/- 27; all p < 0.05). In the control group, LDL cholesterol showed a smaller but significant (p < 0.05) reduction after the second week (baseline, 226 +/- 17 mg/dl; first week, 225 +/- 16; second week, 220 +/- 17; fourth week, 203 +/- 27; eighth week, 198 +/- 27). In conclusion, hypercholesterolemic women treated with atorvastatin show a significant improvement in endothelial reactivity after as early as 2 weeks of therapy. The extent to which these beneficial effects are attributable to cholesterol reduction or to a direct effect of the drug remains to be established.
No takes yet. Share an insight, caveat, or question.
Marchesi et al. (2000) studied Hypercholesterolemia (n=30). Atorvastatin vs. American Heart Association step 1 diet was evaluated on Brachial artery flow-mediated vasodilation (FMV) at 8 weeks (p=<0.05). Atorvastatin daily improved brachial artery flow-mediated vasodilation in postmenopausal hypercholesterolemic women compared to diet.
Synapse has enriched 10 related papers. Consider them for comparative context: